Functional characterization of the Alzheimer's disease Epigenome

项目摘要/摘要 阿尔茨海默病(AD)表现为一种与年龄相关的破坏性进行性神经变性。这 神经变性和随之而来的认知功能丧失困扰着4400多万人 全世界。我们对阿尔茨海默病分子发病机制的了解仍然不完全，也没有治疗方法 预防、阻止或治愈相关的神经变性。这标志着最大的未得到满足的临床需求之一 属于我们这个时代。 经过几十年的研究，全基因组关联研究已经确定了可遗传编码和非编码 导致阿尔茨海默病风险增加的突变。然而，这些突变中的许多在很大程度上仍然存在 其特征不够明确，在AD发病机制中的作用尚不清楚。此外，它已经成为 越来越清楚的是，一个人患阿尔茨海默病的终生风险不仅仅是由基因决定的。在……里面 此外，表观基因组是对DNA施加的所有化学和物理修饰的补充， 不要改变底层的顺序，也被认为起到了至关重要的作用。该项目旨在定义 阿尔茨海默病的表观遗传成分(目标1)和遗传成分(目标2)通过描绘开放的染色质景观 和三维染色质相互作用在脑区域和原代细胞类型的有无和无 广告。这些特征将确定将在功能上进行验证的与AD相关的关键监管要素 采用CRISPR干扰平铺试验(AIM 3)。总而言之，这个项目将提供一个前所未有的 AD表观基因组图，确定AD发病机制的新方面，并提名可能的治疗途径 治疗性干预。 这项工作将在格莱斯顿神经疾病研究所内进行，这是一个理想的环境 进行这种与疾病相关的研究，提供拟议研究所需的所有设施，并提供 早期研究人员的协作和丰富的文化。累积起来，这项工作将推出我的 在表观基因组学和神经疾病的交叉点上的独立研究计划。

Project Summary/Abstract Alzheimer’s disease (AD) manifests as a devastating age-related progressive neurodegeneration. This neurodegeneration and the concomitant loss of cognitive function plagues more than 44 million individuals worldwide. Our understanding of the molecular pathogenesis of AD remains incomplete and no therapies exist to prevent, stop, or cure the associated neurodegeneration. This marks one of the greatest unmet clinical needs of our time. Through decades of research, genome-wide association studies have identified heritable coding and non-coding mutations that lead to an increased risk of developing AD. Many of these mutations, however, remain largely under-characterized and their contribution to AD pathogenesis remains unclear. Moreover, it has become increasingly clear that an individual’s lifetime risk of developing AD is not merely governed by genetics. In addition, the epigenome, the complement of all of the chemical and physical modifications imposed on DNA that do not change the underlying sequence, is also thought to play a crucial role. This project aims to define the epigenetic (Aim 1) and genetic (Aim 2) components of AD through profiling of the open chromatin landscapes and three-dimensional chromatin interactions in brain regions and primary cell types of patients with and without AD. These characterizations will identify key AD-related regulatory elements that will be functionally validated with CRISPR interference tiling assays (Aim 3). Taken together, this project will provide an unprecedented picture of the AD epigenome, identifying novel aspects of AD pathogenesis and nominating putative avenues for therapeutic intervention. This work will be performed within the Gladstone Institute of Neurological Disease which is an ideal environment to perform such disease-relevant research, providing all of the facilities needed for the proposed research and a collaborative and enriching culture for an early stage investigator. Cumulatively, this work will launch my independent research program at the intersection of epigenomics and neurological disease.